Three IPOs raised $495 million this week, led by iRhythm Technologies (IRTC), which popped 53% on its first day. The other two IPOs, CRISPR Therapeutics (CRSP) and Forterra (FRTA), priced below...read more
CRISPR Therapeutics, a preclinical biotech developing therapies based on CRISPR/Cas9 gene editing, raised $56 million by offering 4 million shares at $14, below the range of $15 to $17. CRISPR Therapeutics plans to list on the Nasdaq under the symbol CRSP....read more
Three IPOs are set to raise $518 million in the week ahead. LBO'd industrial pipe maker Forterra is by far the week's largest deal, while CRISPR Therapeutics will attempt to prove that gene editing is more than a pipe dream. High-growth heart monitoring company...read more
CRISPR Therapeutics, a preclinical biotech developing gene editing therapies with CRISPR/Cas9 technology, announced terms for its IPO on Friday. The Basel, Switzerland-based company plans to raise $75 million by offering 4.7 million shares at a price range...read more
US IPO Weekly Recap: Two deals flounder while one soars
Three IPOs raised $495 million this week, led by iRhythm Technologies (IRTC), which popped 53% on its first day. The other two IPOs, CRISPR Therapeutics (CRSP) and Forterra (FRTA), priced below...read more
CRISPR Therapeutics prices IPO at $14, below the range
CRISPR Therapeutics, a preclinical biotech developing therapies based on CRISPR/Cas9 gene editing, raised $56 million by offering 4 million shares at $14, below the range of $15 to $17. CRISPR Therapeutics plans to list on the Nasdaq under the symbol CRSP....read more
US IPO Week Ahead: 3 IPOs feature industrial pipes and high-growth health care
Three IPOs are set to raise $518 million in the week ahead. LBO'd industrial pipe maker Forterra is by far the week's largest deal, while CRISPR Therapeutics will attempt to prove that gene editing is more than a pipe dream. High-growth heart monitoring company...read more
Gene editing biotech CRISPR Therapeutics sets terms for $75 million IPO
CRISPR Therapeutics, a preclinical biotech developing gene editing therapies with CRISPR/Cas9 technology, announced terms for its IPO on Friday. The Basel, Switzerland-based company plans to raise $75 million by offering 4.7 million shares at a price range...read more